In the present study, postmenopausal HR-positive/HER2-negative breast cancer patients with good serum lipid control due to the agents for dyslipidaemia showed significantly longer RFS, and these patients also had significantly lower postoperative NLR. The gene discussed is ERBB2; the disease is breast carcinoma.